Terms: = Kidney tumors AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
54 results:
1. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract] [Full Text] [Related]
2. A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
Knudsen S; Hansen A; Foegh M; Petersen S; Mekonnen H; Jia L; Shah P; Martin V; Frykman G; Pili R
PLoS One; 2023; 18(8):e0290681. PubMed ID: 37647320
[TBL] [Abstract] [Full Text] [Related]
3. A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
Ness DB; Pooler DB; Ades S; Highhouse BJ; Labrie BM; Zhou J; Gui J; Lewis LD; Ernstoff MS
Cancer Med; 2023 Jun; 12(12):13100-13110. PubMed ID: 37148554
[TBL] [Abstract] [Full Text] [Related]
4. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
[TBL] [Abstract] [Full Text] [Related]
5.
Gao J; Meng L; Xu Q; Zhao X; Deng Y; Fu Y; Guo S; He K; Shi J; Wang F; Zhang S; Guo H
Mol Imaging Biol; 2022 Oct; 24(5):759-768. PubMed ID: 35451707
[TBL] [Abstract] [Full Text] [Related]
6. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of Cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
7. Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib.
Nakashima S; Sekine A; Sawa N; Kawamura Y; Kono K; Kinowaki K; Kawada M; Hasegawa E; Akuta N; Suzuki Y; Ohashi K; Takaichi K; Ubara Y; Hoshino J
Intern Med; 2022 Oct; 61(20):3083-3088. PubMed ID: 35342129
[TBL] [Abstract] [Full Text] [Related]
8. CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation.
Liu B; Diaz Arguello OA; Chen D; Chen S; Saber A; Haisma HJ
PLoS One; 2020; 15(5):e0232985. PubMed ID: 32413049
[TBL] [Abstract] [Full Text] [Related]
9. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract] [Full Text] [Related]
10. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
[TBL] [Abstract] [Full Text] [Related]
11. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
[TBL] [Abstract] [Full Text] [Related]
12. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
Kitano H; Kitadai Y; Teishima J; Yuge R; Shinmei S; Goto K; Inoue S; Hayashi T; Sentani K; Yasui W; Matsubara A
Cancer Med; 2017 Oct; 6(10):2308-2320. PubMed ID: 28834289
[TBL] [Abstract] [Full Text] [Related]
13. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
[TBL] [Abstract] [Full Text] [Related]
15. Perivascular pdgfr-β is an independent marker for prognosis in renal cell carcinoma.
Frödin M; Mezheyeuski A; Corvigno S; Harmenberg U; Sandström P; Egevad L; Johansson M; Östman A
Br J Cancer; 2017 Jan; 116(2):195-201. PubMed ID: 27931046
[TBL] [Abstract] [Full Text] [Related]
16. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract] [Full Text] [Related]
17. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
[TBL] [Abstract] [Full Text] [Related]
18. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract] [Full Text] [Related]
19. [Genetic polymorphisms of pdgfr associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].
Sheng X; Kong Y; Tang H; Lian B; Mao L; Chi Z; Cui C; Si L; Wang X; Yan X; Li S; Dai J; Guo J
Zhonghua Yi Xue Za Zhi; 2014 Oct; 94(38):2988-91. PubMed ID: 25547700
[TBL] [Abstract] [Full Text] [Related]
20. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
[TBL] [Abstract] [Full Text] [Related]
[Next]
